ERBB2 and glioblastoma: In mixed tumor-cell models that recapitulate GBM antigen heterogeneity, single-agent NKAB-EGFR or NKAB-ERBB2 lysed only their respective antigen-positive subclones, with lysis rates of ~20%-30% 80.